Sanofi (SNY)
NASDAQ: SNY · Real-Time Price · USD
43.72
-0.06 (-0.14%)
At close: Aug 14, 2026, 4:00 PM EDT
43.83
+0.11 (0.25%)
After-hours: Aug 14, 2026, 7:30 PM EDT
Sanofi Revenue
Sanofi had revenue of 12.30B EUR in the quarter ending June 30, 2026, with 14.58% growth. This brings the company's revenue in the last twelve months to 48.92B, up 6.95% year-over-year. In the year 2025, Sanofi had annual revenue of 46.72B with 5.49% growth.
Revenue (ttm)
48.92B EUR
Revenue Growth
+6.95%
P/S Ratio
1.87
Revenue / Employee
653,595 EUR
Employees
74,846
Market Cap
104.76B USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 46.72B | 2.43B | 5.49% |
| Dec 31, 2024 | 44.29B | 2.67B | 6.41% |
| Dec 31, 2023 | 41.62B | 1.06B | 2.61% |
| Dec 31, 2022 | 40.56B | 1.39B | 3.54% |
| Dec 31, 2021 | 39.18B | 1.81B | 4.83% |
| Dec 31, 2020 | 37.37B | -262.00M | -0.70% |
| Dec 31, 2019 | 37.63B | 1.95B | 5.48% |
| Dec 31, 2018 | 35.68B | -544.00M | -1.50% |
| Dec 31, 2017 | 36.22B | 1.53B | 4.40% |
| Dec 31, 2016 | 34.70B | -165.00M | -0.47% |
| Dec 31, 2015 | 34.86B | 2.86B | 8.94% |
| Dec 31, 2014 | 32.00B | 708.00M | 2.26% |
| Dec 31, 2013 | 31.29B | -4.67B | -12.98% |
| Dec 31, 2012 | 35.96B | 899.00M | 2.56% |
| Dec 31, 2011 | 35.06B | 1.02B | 3.00% |
| Dec 31, 2010 | 34.04B | 2.80B | 8.98% |
| Dec 31, 2009 | 31.23B | 2.42B | 8.38% |
| Dec 31, 2008 | 28.82B | -390.00M | -1.34% |
| Dec 31, 2007 | 29.21B | -282.00M | -0.96% |
| Dec 31, 2006 | 29.49B | 976.00M | 3.42% |
| Dec 31, 2005 | 28.51B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Merck & Co. | 66.57B |
| AbbVie | 64.39B |
| Pfizer | 63.70B |
| AstraZeneca | 61.37B |
| Novartis AG | 56.69B |
| Novo Nordisk | 50.34B |
| Bristol-Myers Squibb Company | 49.19B |
| GSK plc | 44.05B |
SNY News
- 3 days ago - Sanofi price target lowered to EUR 82 from EUR 86 at Morgan Stanley - TheFly
- 5 days ago - Sanofi facing shortages of two drugs for Pompe disease, STAT reports - TheFly
- 8 days ago - Novavax Q2 Earnings Call Highlights - Nasdaq
- 11 days ago - Sanofi's MenQuadfi Wins EC Approval For Use In Six Week Old Infants Against Meningococcal Disease - Nasdaq
- 11 days ago - Sanofi: Sanofi's MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease - Finanz Nachrichten
- 11 days ago - Press Release: Sanofi's MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease - GlobeNewsWire
- 15 days ago - Sanofi SA (SNY) Stock Down 4.5% -- Now Undervalued? GF Score: 70/100 - GuruFocus
- 15 days ago - Sanofi (SNY) Faces Stock Decline Amid CEO's Warning on Drug Pipeline Challenges - GuruFocus